Xilio Therapeutics (XLO) EBITDA Margin (2024 - 2026)
Xilio Therapeutics (XLO) posted EBITDA Margin of -16.91% for Q2 2026, up 156.09 percentage points from -173.00% a year earlier and up 91.95 percentage points from the prior quarter.
Powered by 
Analysis
Xilio Therapeutics (XLO) EBITDA Margin (2024 - 2026) Analysis & Trends
For the trailing twelve months through Jun 30, 2026, EBITDA Margin at Xilio Therapeutics was -46.85%, up 319.61 percentage points year-over-year; for FY2025, it came in at -92.40%, up 836.63 percentage points from FY2024.
- In prior years, Xilio Therapeutics' EBITDA Margin was -929.04% in FY2024.
- Quarterly EBITDA Margin has run from a low of -768.74% in Q4 2024 to a high of -8.33% in Q3 2025 over five years.
- On a year-over-year basis, EBITDA Margin has increased in each of the last five quarters, with an average year-over-year change of +449.36 percentage points over the last five quarters.
- According to Business Quant data, EBITDA Margin for the three prior quarters was -108.86% (Q1 2026), -84.12% (Q4 2025) and -8.33% (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,172.56 Bn | 1,141.15 Bn | 19.71 Bn | 53.49% |
| 2 | Johnson & Johnson | 637.42 Bn | 555.95 Bn | 17.26 Bn | 35.95% |
| 3 | AbbVie | 504.13 Bn | 477.24 Bn | 12.70 Bn | 49.01% |
| 4 | Merck | 377.81 Bn | 332.19 Bn | 12.21 Bn | 6.02% |
| 5 | Novartis Ag | 304.36 Bn | 268.35 Bn | 11.24 Bn | - |
| 6 | Astrazeneca | 267.51 Bn | 241.20 Bn | 12.86 Bn | 33.11% |
| 7 | Amgen | 242.18 Bn | 197.58 Bn | 7.24 Bn | 46.01% |
| 8 | Gilead Sciences | 194.29 Bn | 168.48 Bn | 6.22 Bn | -124.26% |
| 9 | Pfizer | 172.82 Bn | 119.47 Bn | 10.94 Bn | 39.16% |
| 10 | Xilio Therapeutics | 164.34 Mn | -363.33 Mn | - | -16.91% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -16.91% |
| Mar 31, 2026 | -108.86% |
| Dec 31, 2025 | -84.12% |
| Sep 30, 2025 | -8.33% |
| Jun 30, 2025 | -173.00% |
| Mar 31, 2025 | -455.77% |
| Dec 31, 2024 | -768.74% |
| Sep 30, 2024 | -635.53% |
| Jun 30, 2024 | -604.96% |
API Access
Xilio Therapeutics EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=XLO&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "XLO", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=XLO&period=max&api_key=YOUR_API_KEY");
const data = await res.json();